مباشر

Endpoints NewsEnGene's shares crash on updated pivotal bladder cancer data Endpoints NewsAre health insurers out of the woods after a tough 2025?Endpoints NewsBlackstone puts $250M into Anagram to tackle cystic fibrosis complication FierceBiotechAntibodies that stop measles from stabbing cells could become new treatments for the surging virus, study suggests FierceBiotechBeOne shelves 5 cancer programs, halts phase 2 rheumatoid arthritis trial Lonza NewsBMS licenses ADC technology from Lonza - The Pharma Letter BioPharma DiveAngelini to buy Catalyst in $4B play for rare neuro drugs BioPharma DiveEntrada shares dive as Duchenne results disappoint Endpoints NewsEntrada stock falls on Duchenne data; Wegovy expands access CellVirological characteristics of SARS-CoV-2-related coronaviruses dynamically circulating in Southeast Asia CellAffinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections CellMulti-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasome

FierceBiotech ٧ مايو ٢٠٢٦

Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis

Entrada Therapeutics’ Duchenne muscular dystrophy data have fallen well short of expectations, crashing the biotech’s stock as investors evaluated the fallout f...

Entrada Therapeutics’ Duchenne muscular dystrophy data have fallen well short of expectations, crashing the biotech’s stock as investors evaluated the fallout from a key readout expected to validate its platform.